Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

NCT00783692 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00783692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00783692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
Lead sponsor
Millennium Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2008
Completion date
May 31, 2012
Enrollment
1,116 (actual)
Sites
114

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease